Aytu BioPharma, Inc.
Symbol: AYTU
NASDAQ
2.9043
USDDzisiejsza cena rynkowa
-0.9631
Wskaźnik P/E
-0.0159
Wskaźnik PEG
16.17M
Kapitalizacja MRK
- 0.00%
Rentowność DIV
Aytu BioPharma, Inc. (AYTU) Sprawozdania finansowe
Bilans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 81.66 | 23 | 19.4 | 49.6 | |||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.net-receivables | 122.27 | 28.9 | 21.7 | 28.2 | |||||||||||||||||
balance-sheet.row.inventory | 51.6 | 12 | 10.8 | 16.3 | |||||||||||||||||
balance-sheet.row.other-current-assets | 4.13 | 0.9 | 0.6 | 1 | |||||||||||||||||
balance-sheet.row.total-current-assets | 293.27 | 72.8 | 59.9 | 105.2 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 15.7 | 3.9 | 6.3 | 8.7 | |||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 65.8 | |||||||||||||||||
balance-sheet.row.intangible-assets | 235.49 | 59 | 70.6 | 85.5 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 235.49 | 59 | 70.6 | 151.3 | |||||||||||||||||
balance-sheet.row.long-term-investments | -1.38 | -1.4 | 0 | -10.9 | |||||||||||||||||
balance-sheet.row.tax-assets | 1.38 | 1.4 | 0 | 10.9 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 3.36 | 0.8 | 0.8 | 0.5 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 254.55 | 63.6 | 77.7 | 160.4 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 547.82 | 136.5 | 137.6 | 265.7 | |||||||||||||||||
balance-sheet.row.account-payables | 53.09 | 13.5 | 11 | 19.3 | |||||||||||||||||
balance-sheet.row.short-term-debt | 17.7 | 1.6 | 3.9 | 25.5 | |||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 55.92 | 14.7 | 14.3 | 2.8 | |||||||||||||||||
Deferred Revenue Non Current | -1.38 | -1.4 | 0 | -11.2 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1.38 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 82.35 | 7.1 | 49.5 | 7.4 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 118.45 | 28.1 | 27.1 | 18.7 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 4.05 | 0.8 | 2.2 | 3.6 | |||||||||||||||||
balance-sheet.row.total-liab | 402.53 | 97.1 | 91.5 | 128.1 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.retained-earnings | -1230.52 | -304.1 | -288.5 | -178.3 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1375.81 | 343.5 | 334.6 | 315.9 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | 145.29 | 39.4 | 46.1 | 137.6 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 547.82 | 136.5 | 137.6 | 265.7 | |||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-equity | 145.29 | 39.4 | 46.1 | 137.6 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 547.82 | - | - | - | |||||||||||||||||
Total Investments | -1.38 | -1.4 | 0 | -10.9 | |||||||||||||||||
balance-sheet.row.total-debt | 73.62 | 16.4 | 18.2 | 28.3 | |||||||||||||||||
balance-sheet.row.net-debt | -8.04 | -6.6 | -1.2 | -21.3 |
Rachunek przepływów pieniężnych
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -18 | -17.1 | -110.2 | -58.3 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 8.72 | 8.8 | 10.3 | 9.2 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 7.31 | 3.3 | 0 | 22.3 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 3.55 | 6 | 5.2 | 3.6 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 1.71 | -5.8 | -10.9 | 1.7 | |||||||||||||||||
cash-flows.row.account-receivables | -3.79 | -7.2 | 6.5 | 1.5 | |||||||||||||||||
cash-flows.row.inventory | -2.57 | -3.6 | 1.3 | 2.8 | |||||||||||||||||
cash-flows.row.account-payables | 0.19 | 2.4 | -7.7 | -3.2 | |||||||||||||||||
cash-flows.row.other-working-capital | 7.87 | 2.6 | -11 | 0.6 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 2.81 | -0.4 | 76.7 | -4.5 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 6.11 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | -2.3 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | -3.2 | -2.8 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-investing-activites | -0.4 | -0.1 | -0.1 | 2.4 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -0.4 | -0.1 | -3.2 | -2.8 | |||||||||||||||||
cash-flows.row.debt-repayment | -2.39 | -2.3 | -172.5 | -54.9 | |||||||||||||||||
cash-flows.row.common-stock-issued | 3.93 | 15.6 | 11.7 | 45.1 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-financing-activites | -7.22 | -4.4 | 162.3 | 40.2 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -5.68 | 8.9 | 1.5 | 30.3 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 0.03 | 3.6 | -30.5 | 1.6 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 81.66 | 23 | 19.4 | 49.9 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 81.63 | 19.4 | 49.9 | 48.3 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 6.11 | -5.1 | -28.8 | -26 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | -2.3 | |||||||||||||||||
cash-flows.row.free-cash-flow | 6.11 | -5.1 | -28.8 | -28.3 |
Wiersz rachunku zysków i strat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 98.5 | 107.4 | 96.7 | 65.6 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 36.2 | 40.8 | 44.4 | 36.4 | |||||||||||||||||
income-statement-row.row.gross-profit | 62.29 | 66.6 | 52.3 | 29.2 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 2.45 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 25.68 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 34.78 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | -1.94 | -4.8 | 4.1 | 6 | |||||||||||||||||
income-statement-row.row.operating-expenses | 65.31 | 79 | 88.4 | 67.4 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 101.52 | 119.7 | 132.8 | 103.9 | |||||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.interest-expense | -3.86 | 0 | 147.5 | 0 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 34.78 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -11.55 | -4.7 | -147.5 | -19.8 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | -1.94 | -4.8 | 4.1 | 6 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | -11.55 | -4.7 | -147.5 | -19.8 | |||||||||||||||||
income-statement-row.row.interest-expense | -3.86 | 0 | 147.5 | 0 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 5.71 | 4.8 | 4.1 | 23.7 | |||||||||||||||||
income-statement-row.row.ebitda-caps | -0.31 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | -8.26 | -17.1 | 37.2 | -38.2 | |||||||||||||||||
income-statement-row.row.income-before-tax | -17.17 | -17.1 | -110.3 | -58 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 1.25 | -0.1 | -0.1 | 0.3 | |||||||||||||||||
income-statement-row.row.net-income | -16.64 | -17.1 | -110.2 | -58.3 |
Często zadawane pytania
Ile wynosi Aytu BioPharma, Inc. (AYTU) aktywów ogółem?
Aytu BioPharma, Inc. (AYTU) całkowite aktywa to 136463000.000.
Jaki jest roczny przychód przedsiębiorstwa?
Roczny przychód to 45033000.000.
Jaka jest marża zysku firmy?
Marża zysku firmy to 0.632.
Czym są wolne przepływy pieniężne firmy?
Wolne przepływy pieniężne to 1.108.
Jaka jest marża zysku netto przedsiębiorstwa?
Marża zysku netto to -0.169.
Jaki jest całkowity przychód firmy?
Całkowity przychód to -0.084.
Co to jest Aytu BioPharma, Inc. (AYTU) zysk netto (dochód netto)?
Zysk netto (dochód netto) wynosi -17051000.000.
Jakie jest całkowite zadłużenie firmy?
Całkowite zadłużenie to 16361000.000.
Ile wynoszą koszty operacyjne?
Wydatki operacyjne to 78961000.000.
Jaka jest wartość gotówki firmy?
Środki pieniężne przedsiębiorstwa to 19529000.000.